| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8712449 | Dermatologica Sinica | 2018 | 5 Pages |
Abstract
Our study showed that the therapeutic management of Turkish dermatologists was parallel to the European Urticaria Guidelines. The high utility of omalizumab as a third line regimen improved patient care. Nevertheless there is a need for centers experienced in urticaria to refer antihistamine-resistant patients where third-line treatment options can not be implemented.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Emek Kocatürk, Etikan Piril, Taskapan Oktay, Atakan Nilgun, Erdem Teoman, Utas Serap, Savk Ekin, Bulbul Baskan Emel, Koca Rafet, Aktan Sebnem,